Narcolepsy Market Size & Share | Industry Analysis 2021-2027

The narcolepsy market size is estimated to reach US$ 4,537.9 million by 2027 from US$ 2,026.8 million in 2018; it is estimated to grow at a CAGR of 9.5% during 2019-2027.

Narcolepsy is a rare long-term brain disorder characterized by excessive sleepiness, sleep paralysis, hallucinations, and episodes of cataplexy among certain patients. Narcolepsy is known to occur equally among men and women, and the global incidence of narcolepsy is estimated to be roughly 1 in 2,000 people. People with narcolepsy feel very sleepy during the day and may involuntarily fall asleep during normal activities. Furthermore, narcolepsy is characterized by excessive drowsiness and sleep episodes. Narcolepsy makes it difficult for people to stay awake for lengthy periods of time and makes them sleepy for most of the day.

The narcolepsy market growth is attributed to the rising prevalence of sleep-related neurological disorders, emerging local pharmaceutical and biopharmaceutical companies, and increasing awareness regarding neurological disorders. However, side effects and risks associated with the narcolepsy medications and delayed diagnosis and misdiagnosis of the disease are likely to pose a negative impact on the narcolepsy market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Narcolepsy Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

 

Market Insights
Rising Prevalence of Sleep-Related Neurological Disorders Drives Narcolepsy Market

The range of sleep disorders that are treated by neurologists is wide and includes conditions such as insomnia, sleep apnea, restless legs syndrome, and narcolepsy. These disorders cause disruptions in the normal sleep–wake mechanisms causing endogenous abnormalities. Neurological sleep-related disorders are expected to increase in the coming years, as a large portion of the population will enter old age. According to the National Institute of Health (NIH), approximately 40 million Americans suffer from neurological diseases in the US and 20 million people experience occasional sleeping problems.

Over the last decades, much has been learned about the pathophysiology of narcolepsy. According to the National Center for Biotechnology Information, the prevalence of narcolepsy with cataplexy has been examined in many studies and falls between 25 and 50 per 100,000 people. Moreover, according to the Narcolepsy Network 2017, the condition affects 1 in every 2,000 people in the US, i.e., 200,000 Americans and approximately 3 million worldwide. Moreover, the American Sleep Apnea Association reports that sleep-related problems affect 50–70 million Americans of all ages and socioeconomic classes. However, important disparities in the prevalence and severity of certain sleep disorders have been identified in minorities and underserved populations. More than 50 million Americans already suffer from over 80 different sleep disorders and another 20–30 million suffer from intermittent sleep problems each year.

People with narcolepsy suffer from chronic daytime sleepiness and episodes in which they fall asleep unexpectedly during the day. These "sleep attacks" can occur at any time, during any activity. Sleep attacks are not limited to periods of dull or low engagement activities, but can happen during school or work hours, in the middle of a conversation, while eating, while exercising or playing sports, or even while driving. Thus, the surge in the prevalence of sleep-related neurological disorders is likely to propel the narcolepsy market’s trends forward during the forecast period.

Type-Based Insights

The global narcolepsy market, based on type, is segmented into narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy.  The narcolepsy with cataplexy segment held the largest share among the type subsegments in the narcolepsy market in 2018 and is also anticipated to witness a similar trend over the forecast period. Narcolepsy with cataplexy also referred to as Narcolepsy Type-1 is a rare neurological disorder that is diagnosed based on having low levels of a brain hormone (hypocretin) or reported events of cataplexy within an individual. Cataplexy refers to sudden and uncontrollable muscle weakness or paralysis that majorly occurs in a day and is often triggered by strong emotions, such as excitement or laughter. The person loses muscle tone and can have a slack jaw, broken speech, buckled knees, or total weakness in their face, arms, legs, and trunk, without much of a warning. The loss of muscle tone in cataplexy occurs because of the inability to regulate sleep and awake states. In about 10% of cases of narcolepsy, cataplexy is the first symptom to appear and can be misdiagnosed as a seizure disorder.

Product-Based Insights

The global narcolepsy market, based on product, is segmented into central nervous system (CNS) stimulants, sodium oxybate, and antidepressants. The sodium oxybate segment held the largest narcolepsy market share in 2018. Sodium oxybate is also known as gamma-hydroxybutyrate (GHB) is known to reduce daytime sleepiness and cataplexy by improving nighttime sleep in patients with narcolepsy. GHB is used to treat narcolepsy, a condition that causes severe daytime sleepiness. Sodium oxybate can decrease daytime sleepiness and also reduce the number of sudden short attacks of weak/paralyzed muscles (known as cataplexy) that can occur in patients with narcolepsy. This medication is highly effective for cataplexy. Sodium oxybate helps improve nighttime sleep, which is often poor in narcolepsy. In high doses, it may also help control daytime sleepiness. It must be taken in two doses, one at bedtime and one up to four hours later.

Distribution Channel-Based Insights

The global narcolepsy market, based on distribution channel, is divided into hospital pharmacies and retail pharmacies. The hospital pharmacies segment led the narcolepsy market in 2018. Hospital pharmacies refers to the medical pharmacies situated usually in the hospital premises. These pharmacies stock a large number of medications that majorly include specialized and investigational medications. Hospital pharmacies typically provide medications for hospitalized patients only and are not retail establishments. Hospital pharmacies may provide a huge quantity of medications per day allocated to the wards and intensive care units according to a patient's medication schedule. Larger hospitals may use automated transport systems to aid in the efficient distribution of medications.

 

Narcolepsy Market Regional Insights

The regional trends and factors influencing the Narcolepsy Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Narcolepsy Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Narcolepsy Market Report Scope

Narcolepsy Market Players Density: Understanding Its Impact on Business Dynamics

The Narcolepsy Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Narcolepsy Market are:

1. Bioprojet
2. Teva Pharmaceutical Industries Ltd.
3. Jazz Pharmaceuticals, Inc.
4. Graymark Healthcare, Inc.
5. Arena Pharmaceuticals, Inc.

Disclaimer: The companies listed above are not ranked in any particular order.

Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world. The market share is anticipated to flourish with the development of new innovative products by market players. Some of the market participants offering products are Teva Pharmaceutical Industries Ltd; Jazz Pharmaceuticals plc; Arena Pharmaceuticals, Inc; Graymark Healthcare, Inc; Novartis AG; Takeda Pharmaceutical Company Limited; Mylan N.V.; BIOPROJET; Shionogi & Co., Ltd; and Ligand Pharmaceuticals, Inc.